AtG Therapeutics is a breakthrough player in the oncology field and a recently created spinoff from Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institute of Oncology (ICO). AtG is developing a new treatment to prevent anti-angiogenics resistance, currently in the preclinical phase, and a prototype of a patient selector.
This project was supported by international and national institutions, including the European Research Council (ERC), the “La Caixa” Foundation, the Spanish Association Against Cancer (AECC), the Carlos III Health Institute, and La Prospectiva en Salud en Spain (FIPSE).
AtG Therapeutics has just closed its first financing round, after its incorporation as a company. AtG has raised more than half a million euros.
Inveniam Group supported AtG Therapeutics in this pre-seed round by bringing investors and investment opportunities from our extensive investor network. We look forward to continued collaboration and success with AtG Therapeutics.